Tafazoli Alireza, Behjati Farkhondeh, Farhud Dariush D, Abbaszadegan Mohammad Reza
Department of Analysis and Bioanalysis of Medicine, Faculty of Pharmacy with the Division of Laboratory Medicine, Medical University of Bialystok, Bialystok, Poland.
Department of Endocrinology, Diabetology and Internal Medicine, Clinical Research Center, Medical University of Bialystok, Bialystok, Poland.
Iran J Public Health. 2019 Mar;48(3):371-378.
Down syndrome (DS) is one of the most prevalent genetic disorders in humans. The use of new approaches in genetic engineering and nanotechnology methods in combination with natural cellular phenomenon can modify the disease in affected people. We consider two CRISPR/Cas9 systems to cut a specific region from short arm of the chromosome 21 (Chr21) and replace it with a novel designed DNA construct, containing the essential genes in chromatin remodeling for inactivating of an extra Chr21. This requires mimicking of the natural cellular pattern for inactivation of the extra X chromosome in females. By means of controlled dosage of an appropriate Nano-carrier (a surface engineered Poly D, L-lactide-co-glycolide (PLGA) for integrating the relevant construct in Trisomy21 brain cell culture media and then in DS mouse model, we would be able to evaluate the modification and the reduction of the active extra Chr21 and in turn reduce substantial adverse effects of the disease, like intellectual disabilities. The hypothesis and study seek new insights in Down syndrome modification.
唐氏综合征(DS)是人类最常见的遗传疾病之一。将基因工程和纳米技术方法的新方法与自然细胞现象相结合,可以改变受影响人群的疾病状况。我们考虑使用两种CRISPR/Cas9系统从21号染色体(Chr21)的短臂上切割特定区域,并用一种新设计的DNA构建体替换它,该构建体包含染色质重塑中的必需基因,用于使额外的Chr21失活。这需要模仿女性额外X染色体失活的自然细胞模式。通过控制适当的纳米载体(一种表面工程化的聚D,L-丙交酯-共-乙交酯(PLGA))的剂量,将相关构建体整合到21三体脑细胞培养基中,然后整合到DS小鼠模型中,我们将能够评估活性额外Chr21的修饰和减少,进而减少该疾病的重大不良影响,如智力残疾。该假设和研究旨在寻求唐氏综合征修饰方面的新见解。